JP2020517631A5 - - Google Patents

Download PDF

Info

Publication number
JP2020517631A5
JP2020517631A5 JP2019556830A JP2019556830A JP2020517631A5 JP 2020517631 A5 JP2020517631 A5 JP 2020517631A5 JP 2019556830 A JP2019556830 A JP 2019556830A JP 2019556830 A JP2019556830 A JP 2019556830A JP 2020517631 A5 JP2020517631 A5 JP 2020517631A5
Authority
JP
Japan
Prior art keywords
composition
oligonucleotide
population
item
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019556830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517631A (ja
JP7186721B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/028263 external-priority patent/WO2018195250A1/en
Publication of JP2020517631A publication Critical patent/JP2020517631A/ja
Publication of JP2020517631A5 publication Critical patent/JP2020517631A5/ja
Application granted granted Critical
Publication of JP7186721B2 publication Critical patent/JP7186721B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019556830A 2017-04-19 2018-04-19 Igf-1r阻害のためのp-エトキシ核酸 Active JP7186721B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762487420P 2017-04-19 2017-04-19
US62/487,420 2017-04-19
PCT/US2018/028263 WO2018195250A1 (en) 2017-04-19 2018-04-19 P-ethoxy nucleic acids for igf-1r inhibition

Publications (3)

Publication Number Publication Date
JP2020517631A JP2020517631A (ja) 2020-06-18
JP2020517631A5 true JP2020517631A5 (enExample) 2021-05-20
JP7186721B2 JP7186721B2 (ja) 2022-12-09

Family

ID=63856102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556830A Active JP7186721B2 (ja) 2017-04-19 2018-04-19 Igf-1r阻害のためのp-エトキシ核酸

Country Status (8)

Country Link
US (1) US20210115451A1 (enExample)
EP (1) EP3612162A4 (enExample)
JP (1) JP7186721B2 (enExample)
KR (1) KR102657218B1 (enExample)
CN (1) CN110650727A (enExample)
AU (1) AU2018255353B2 (enExample)
CA (1) CA3057974A1 (enExample)
WO (1) WO2018195250A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102755601B1 (ko) 2015-10-14 2025-01-17 바이오-패쓰 홀딩스 인크. 리포좀 제제를 위한 p-에톡시 핵산
US10927379B2 (en) 2016-09-16 2021-02-23 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
IL269608B2 (en) 2017-04-19 2024-06-01 Bio Path Holdings Inc Compositions comprising p-ethoxy nucleic acids for stat3 inhibition for use in treating cancer or autoimmune disease
US12234457B2 (en) 2017-04-19 2025-02-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for BCL2 inhibition
CN114369130B (zh) * 2021-12-28 2023-10-03 杭州天龙药业有限公司 修饰的硫代寡核苷酸及其应用
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015886A (en) * 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) * 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
AU5479899A (en) * 1998-08-13 2000-03-06 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-i receptor
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US10206942B2 (en) * 2015-04-10 2019-02-19 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
KR102755601B1 (ko) * 2015-10-14 2025-01-17 바이오-패쓰 홀딩스 인크. 리포좀 제제를 위한 p-에톡시 핵산

Similar Documents

Publication Publication Date Title
JP2020517631A5 (enExample)
Scheicher et al. Protamine–oligonucleotide-nanoparticles: Recent advances in drug delivery and drug targeting
JP6768664B2 (ja) 分子の細胞内送達のためのペプチドおよびナノ粒子
US20210214728A1 (en) Compositions for delivery of cargo to cells
US8440811B2 (en) DNA nanostructures that promote cell-cell interaction and use thereof
JP2021500064A5 (enExample)
AU2017203714A1 (en) Immunostimulatory oligonucleotides
IL273980B2 (en) Phosphorylated tau peptide preparations and uses thereof
AU2012303619B2 (en) Pathogen and substance traps
JP2020517645A5 (enExample)
US20170175122A1 (en) Rna-based compositions and adjuvants for prophylactic and therapeutic treatment
EP2687204B1 (en) Vector for pulmonary delivery, inducing agent, and uses
JP2015521626A5 (enExample)
CN101874112A (zh) 特别是作为免疫刺激剂/佐剂的式(Ⅰ):G1XmGn或式(Ⅱ):C1XmCn的核酸
WO2011049750A1 (en) Multifunctional aptamer-nucleic acid nanostructures for tumor-targeted killing
TW201723178A (zh) 具拮抗pdl1功能的適體分子於癌症治療之應用
JPH11504926A (ja) 核酸リガンド複合体
JP2021500016A5 (enExample)
JP2020526530A5 (enExample)
JP2019534899A (ja) 脂質ナノ粒子用膜材料組成物
KR20250002732A (ko) 중추 신경계 전달용 지질 나노입자 제제
JP2020517646A5 (enExample)
CN109464397A (zh) 一种基于生物矿化的氧化石墨烯多药共载系统及其制备方法和应用
JP6715775B2 (ja) 非凝集性免疫賦活化オリゴヌクレオチド
JPWO2020002540A5 (enExample)